

# Pankaj Trivedi

## Curriculum Vitae

### Part I – General Information

|                  |  |
|------------------|--|
| Full Name        | Pankaj Trivedi   |
| Present position | Full Professor, Department of Experimental Medicine, Sapienza University, Rome, Italy. |

### Part II – Education

| Type                            | Year | Institution  | Notes (degree, thesis title)  |
|---------------------------------|------|--|---|
| Bachelor of Science             | 1983 | Sardar Patel University<br>Vallabh Vidyanagar<br>Pincode: 388120, Gujarat, India | B.Sc. (Microbiology)  |
| Master of Science               | 1985 | Sardar Patel University<br>Vallabh Vidyanagar<br>Pincode: 388120, Gujarat, India | M.Sc. (Microbiology)  |
| Ph.D.                           | 1995 | Karolinska Institute, Stockholm, Sweden  | Doctoral dissertation title: Epstein-Barr virus growth transformation associated proteins: Effects on immunogenicity and phenotype of the tumor cells |
| National Scientific eligibility | 2014 | ANVUR  | Eligibility for full Professor in the sector 06/N1, call 2012   |

### Part III – Appointments

#### III A – Academic Appointments

| Start    | End      | Institution  | Position            |
|----------|----------|--|---------------------|
| Sep 1995 | Sep 1998 | Neuromed Institute, Pozzilli, Italy                            | Postdoc             |
| Oct 1998 | Oct 2001 | Department of experimental Medicine, Sapienza University, Rome | Senior Postdoc      |
| Nov 2001 | Oct 2020 | Department of Experimental Medicine, Sapienza University, Rome | Associate Professor |

|          |         |  |                |
|----------|---------|--|----------------|
| Nov 2020 | Present | Department of Experimental Medicine, Sapienza University, Rome | Full Professor |
|----------|---------|--|----------------|

### III B – Other Appointments

| Start    | End        | Institution   | Position   |
|----------|------------|---|--|
| Sep 2001 | Oct 2001   | Hokkaido University Medical School, Sapporo, Japan                        | Visiting Scientist   |
| Oct 2016 | March 2017 | Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA | Visiting Professor   |
| 2015     | present    | Sapienza University, Rome   | Responsible for the international academic mobility (RAM), Erasmus program for Physiotherapy undergrad course, San Giovanni Addolorata Hospital. |

### III C – Editorial/reviewer expertise

|              | Journal                                      | Position   |
|--------------|--|--|
| 2012-Present | MicroRNA journal                             | Associate Editor   |
| 2018         | International Journal of Molecular Sciences  | Guest Editor, Special issue on microRNAs in human diseases |
| 2019-present | Scientific Reports, Nature Publishing Group. | Editorial Board Member                                     |
| 2019         | BMC Pulmonary Medicine                       | Reviewer   |
| 03/2019      | Oncology Letters                             | Reviewer   |
| 10/2018      | Frontiers in Immunology                      | Reviewer   |
| 08/2018      | Scientific Reports                           | Reviewer   |
| 2018         | Journal of Cellular Physiology               | Reviewer   |
| 11/2018      | PLoS One                                     | Reviewer   |
| 03/2018      | Eur J Hematology                             | Reviewer   |
| 09/2018      | Scientific Reports                           | Reviewer   |
| 06/2018      | Cell Death and Differentiation               | Reviewer   |
| 2018         | International Journal of Cancer              | Reviewer   |
| 06/2017      | Scientific Reports                           | Reviewer   |
| 2017         | Cancers                                      | Reviewer   |
| 2017         | Molecular Carcinogenesis                     | Reviewer   |
| 2017         | Pathogens                                    | Reviewer   |

The list of journals for which I have served recently as reviewer can be found at:  
<https://publons.com/researcher/1263361/pankaj-trivedi/>

### III D – International Grant reviewer

|      | Grant Agency                                       | Position |
|------|--|----------|
| 2010 | AICR, (now known as Worldwide Cancer research), UK | Reviewer |
| 2013 | Food and Health Bureau of the Government of the    | Reviewer |

|      |  |          |
|------|--|----------|
|      | Hong Kong Special administrative region, People's Republic of China                                |          |
| 2013 | Maturation and Accelerating Translation With INdustry, MATWIN, French Cancéropôles network, France | Reviewer |

#### Part IV A – Teaching experience (undergraduate, post graduate and doctorate courses)

| Year         | Institution   | Lecture/course   |
|--------------|---|--|
| 1992         | Department of General Pathology and Experimental Medicine, Sapienza University Rome                               | Invited lecturer. Epstein-Barr virus and lymphoma: A practical course.                           |
| 1996-1998    | Neuromed Institute, Pozzilli (IS), Degree course in Physiotherapy, Sapienza University                            | Scientific English   |
| 2001-present | Degree course in Physiotherapy, San Giovanni Addolorata Hospital, Course C, Sapienza University, Rome             | Coordinator and docent of General Pathology and Microbiology                                     |
| 2017-present | Sapienza University, Rome   | President of the Degree course in Physiotherapy, corso C, San Giovanni Addolorata Hospital, Rome |
| 2001-present | Sapienza University, Rome   | Supervision of 6 doctorate students, PhD degree course in Experimental Medicine                  |
| 2001-present | Sapienza University, Rome   | Supervision of experimental thesis of 10 undergraduate students                                  |
| 2004-2006    | Ph.D. school in the Pathologies of the neck organs (Patologie degli organi del collo), Sapienza University, Rome. | Board Member   |
| 2012-2019    | Sapienza University, Rome. PhD school in life sciences (Dottorato: Scienze della vita)                            | Board Member   |
| 2013-present | Sapienza University, Rome   | Master in Molecular Virology, Sapienza University  |
| 2014-present | Sapienza University, Rome   | Undergraduate course in Biotechnology. Lectures: MicroRNA and diseases                           |

#### Part IV B: International Ph.D. Examiner and Erasmus supervisor

|      | Institution                | Thesis title  |
|------|----------------------------|---|
| 2018 | Calcutta University, India | Analysis of Regulation of Self Renewal Pathways And EGFR Expression In Uterine Cervical Carcinoma Of Indian Patients. Candidate: Dr. Sudip Sammader                                     |
| 2017 | Calcutta University, India | Molecular Analysis Of DNA Damage Response Pathways In Breast Cancer. Candidate: Dr. Hemantika Dasgupta  |
| 2016 | Calcutta University, India | Effect of Tea and Tea Polyphenols (EGCG and TF) on Stem Cell renewal pathways during oral and liver carcinogenesis induced by N-nitrosodiethylamine (NDEA): Candidate: Dr. Subhayan Sur |

|              |  |   |
|--------------|--|---|
| 2014         | Jadavpur University, India                 | Analysis of HPV 16/18 profiling and identification of candidate tumor suppressor genes loci in chromosome 11 associated with development of uterine cervical carcinoma of Indian patients. Candidate: Dr. Dipanjana Indra |
| 2012         | Jadavpur University, India                 | Molecular analysis of development of carcinogenesis in an experimental model of 20 methyl cholanthrene induced transformed murine embryonal fibroblast cells in culture. Candidate: Dr. Sudeshna Mukherjee                |
| 2015-present | Erasmus Incoming students to Sapienza Uni. | Aberdeen University, UK; Université Paris Descartes, France and Aristotle University, Thessaloniki, Greece.   |

### Part V A - Society memberships, Fellowships, Awards, Honors

| Year         | Title   |
|--------------|---|
| 2017-present | Associate Member of the American Association for Cancer Research (AACR)   |
| 2018-present | Founding Member of the Italian Society of translational Research and Paramedical professions (SIRTEPS).                   |
| 2016         | Winner of Yamagiwa-Yoshida Award Memorial International Cancer Study Grant, Union for International Cancer Control, UICC. |
| 1996-97      | International AIDS research fellowship from the Italian national health Institute (Istituto Superiore di Sanità)          |
| 1998         | Fellowship from the Pasteur Institute, International Network, Rome, Italy   |
| 1999-2001    | Fellowship from Italian Cancer research Association (AIRC)  |
| 1995         | Travel grant from the Swedish Cancer Society, Cancerfonden, Sweden  |
| 1991-1995    | Fellowship from Karolinska Institute, Stockholm, Sweden   |
| 1986-91      | Fellowship from the Cancer Research Institute, New York and Concern foundation, Los Angeles, USA                          |

### Part V B- Patent and media coverage

|      |   |
|------|---|
| 2019 | Patent WO/2019/232160 RNA aided immunotherapeutics. Inventors: Trivedi (Sapienza), Slack (Harvard Medical School, Boston, USA) and Anastasiadou (Harvard/Sapienza).<br><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019232160&amp;_cid=P10-K6248M-32632-1">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019232160&amp;_cid=P10-K6248M-32632-1</a>  |
| 2018 | 1: News coverage: Anastasiadou et al, Clinical Cancer Research, 2020.<br><a href="https://www.uniroma1.it/it/notizia/piccoli-rna-grandi-speranze-scoperta-una-nuova-molecola-rallentare-la-crescita-tumorale-dei">https://www.uniroma1.it/it/notizia/piccoli-rna-grandi-speranze-scoperta-una-nuova-molecola-rallentare-la-crescita-tumorale-dei</a><br><br><a href="https://www.uniroma1.it/sites/default/files/field_file_allegati/segnalazioni_dei_media_14.pdf">https://www.uniroma1.it/sites/default/files/field_file_allegati/segnalazioni_dei_media_14.pdf</a><br><br>2: News coverage of Anastasiadou et al, Leukemia 2018.<br><a href="https://www.uniroma1.it/it/notizia/dallalleanza-sapienza-harvard-un-nuovo-approccio-immunoterapia-del-cancro">https://www.uniroma1.it/it/notizia/dallalleanza-sapienza-harvard-un-nuovo-approccio-immunoterapia-del-cancro</a><br><br><a href="https://tg24.sky.it/salute-e-benessere/2018/07/12/tumori-terapia-sistema-immunitario.html">https://tg24.sky.it/salute-e-benessere/2018/07/12/tumori-terapia-sistema-immunitario.html</a><br><br><a href="https://oncolife.it/blog/novita-dalla-ricerca/immunoterapia-del-cancro-di-origine-infettiva-un-nuovo-approccio/">https://oncolife.it/blog/novita-dalla-ricerca/immunoterapia-del-cancro-di-origine-infettiva-un-nuovo-approccio/</a><br><br><a href="https://www.researchitaly.it/en/success-stories/health-new-strategies-to-prevent-">https://www.researchitaly.it/en/success-stories/health-new-strategies-to-prevent-</a> |

|   |
|---|
| <p><a href="https://www.sanitainformazione.it/salute/sapienza-harvard-immunoterapia/">tumours-from-escaping-the-immune-system/</a></p> <p><a href="https://www.sanitainformazione.it/salute/sapienza-harvard-immunoterapia/">https://www.sanitainformazione.it/salute/sapienza-harvard-immunoterapia/</a></p> <p><a href="https://issuu.com/onbpress/docs/gdb_settembre_pagina_singola">https://issuu.com/onbpress/docs/gdb_settembre_pagina_singola</a>, Il giornale dei Biologi, 5, Settembre 2018, page 26</p> |
|---|

## Part VI – Research Activities

| Key words   | Brief Description  |
|---|--|
| <b>EBV</b><br><b>Burkitt lymphoma</b><br><b>DLBCL</b><br><b>microRNA</b><br><b>Biomarkers</b><br><b>Latency</b><br><b>Immune checkpoints</b><br><b>Tumor immunogenicity</b><br><b>RNA aided immunotherapy</b><br><b>3D microfluidic chips</b> | <p><b>The unifying theme of my research interests is to understand molecular mechanisms underlying oncogenic potential of the first human oncogenic virus, namely, Epstein-Barr virus (EBV) and how the results obtained could be translated into novel diagnostic, prognostic and therapeutic approaches for EBV associated cancers.</b></p> <p><b>a. Establishment of a murine model to investigate immunogenicity of viral proteins:</b> Early in my career at Karolinska Institute in Stockholm, <i>I established a syngeneic murine model system to evaluate immunogenicity of EBV encoded latent proteins. I showed that EBNA1, a viral protein present in all EBV infected tumor cells is non-immunogenic.</i> Using the same model, subsequently I demonstrated that LMP1 which is expressed in all nasopharyngeal carcinomas (NPC), has evolved to be non-immunogenic.</p> <p><b>b. EBV and phenotypic changes in associated cancers:</b> Another important focus of my research is how EBV induces phenotypic changes in the infected tumor cells which help the virus to avoid immune surveillance. My colleagues and I were the first to report how EBNA2 a virally encoded protein increases BCL2 expression in B cell lymphomas. In epithelial cell model, we showed that E-Cadherin is downregulated by EBV encoded LMP1. I also showed that EBV infected primary effusion lymphomas (PELs) are more tumorigenic than KSHV only positive PELs.</p> <p><b>c. EBV and cellular oncogene interaction:</b> Together with my colleagues, I have discovered that EBV alters TCL1 oncogene when the infected cells have latency I type viral gene expression. Interestingly, we found that latency III type viral gene expression pattern has the opposite effect on TCL1 expression. <b>Our data showing that latency III related viral genes can negatively affect oncogenes could be critical in designing efficient RNA based therapeutic strategies for EBV associated cancers.</b></p> <p><b>d. EBV and alteration of cellular miRNA in B cell lymphomas:</b> Since last 12 years or so, my major research focus is how EBV alters cellular miRNAs to make the infected cells more tumorigenic. My group has been among the first to find that two critically important proteins encoded by EBV, namely EBNA2 and LMP1 can profoundly alter cellular miRNA expression profile. Furthermore, we discovered that in lymphomas, miRNA signature profile depends on the presence of EBV. <b>These data are</b></p> |

|  |  |
|--|--|
|  | <p><b>relevant for development of new miRNA based diagnostic approaches for B cell lymphoma.</b></p> <p><b>e. EBV, EBNA2 and Immune checkpoint alteration by dysregulation of miRNAs:</b> We have recently shown how EBV encoded EBNA2 downregulates cellular miRNAs and in particular miR-34 to increase PD-L1 expression, which helps the virus infected cells evade immune surveillance. <i>My lab has developed a novel tumor immunogenicity test system based on 3D microfluidic chips, with enormous translational bearings.</i> Given the fact that cancer immunotherapy is successful only in about 30 % of cases, we are currently investigating the combinatorial potential of noncoding RNA and immune checkpoint blockers to reconstitute tumor immunogenicity. <b>A joint international patent (PCT) filed together with my collaborators at Harvard Medical School in Boston, USA, emphasizes the conspicuous translational significance of these results.</b></p> |
|--|--|

## Part VII

An up-to-date list of my publications can be found at:

<https://www.ncbi.nlm.nih.gov/myncbi/1ZeyeluR8p8A-/bibliography/public/>

1: Cuomo L, **Trivedi P**, Wang F, Winberg G, Klein G, Masucci MG. Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B lymphoma lines in allogeneic mixed lymphocyte cultures. *Eur J Immunol.* 1990 Oct;20(10):2293-9. doi: 10.1002/eji.1830201019. ( **I.F. 4.695 J. Citation Report (JCR), Cit: 34 Scopus**)

2: **Trivedi P**, Masucci MG, Winberg G, Klein G. The epstein-Barr-virus-encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. *Int J Cancer.* 1991 Jul 9;48(5):794-800. doi: 10.1002/ijc.2910480527. (**I.F. 4.982 J Citation report Cit: 49 Scopus**)

3: Finke J, Fritzen R, Ternes P, **Trivedi P**, Bross KJ, Lange W, Mertelsmann R, Dölken G. Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. *Blood.* 1992 Jul 15;80(2):459-69. ( **I.F. 16.601, J Citation Report, Cit: 127 Scopus**)

4: Cuomo L, Ramquist T, **Trivedi P**, Wang F, Klein G, Masucci MG. Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV-negative Burkitt lymphoma line. *Int J Cancer.* 1992 Jul 30;51(6):949-55. (**I. F. 4.982, J Citation Report, Cit: 26 Scopus**)

5. Fåhraeus R, Chen W, **Trivedi P**, Klein G, Obrink B. Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells. *Int J Cancer.* 1992 Nov 11;52(5):834-8. ( **I. F. 4.982, J Citation Reports , Cit: 59 Scopus**)

6. Cuomo L, **Trivedi P**, de Campos-Lima PO, Zhang QJ, Ragnar E, Klein G, Masucci MG. Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines. *Mol Immunol.* 1993 Apr;30(5):441-50. (**I.F. 3.064, J. Citation Reports, Cit: 9 Scopus**)

- 7: **Trivedi P**, Cuomo L, de Campos-Lima PO, Imreh MP, Kvarnung K, Klein G, Masucci MG. Integration of a short Epstein-Barr virus DNA fragment in a B95-8 virus converted Burkitt lymphoma line expressing Epstein-Barr nuclear antigens EBNA2 and EBNA5. *J Gen Virol*. 1993 Jul;74 (Pt 7):1393-8. doi: 10.1099/0022-1317-74-7-1393. (I.F. 2.809, J Citation reports, Cit: 5 Scopus)
- 8: Masucci MG, Gavioli R, de Campos-Lima PO, Zhang QJ, **Trivedi P**, Dolcetti R. Transformation-associated Epstein-Barr virus antigens as targets for immune attack. *Ann N Y Acad Sci*. 1993 Aug 12;690:86-100. doi: 10.1111/j.1749-6632.1993.tb43999.x. Review. (I.F: 4.039, J Citation Report, Cit: 8 Scopus)
- 9: **Trivedi P**, Hu LF, Chen F, Christensson B, Masucci MG, Klein G, Winberg G. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. *Eur J Cancer*. 1994;30A(1):84-8. doi: 10.1016/s0959-8049(05)80024-3. (I.F. 6.680, J Citation Reports, Cit: 87 Scopus)
- 10: **Trivedi P**, Zhang QJ, Chen F, Minarovits J, Ekman M, Biberfeld P, Klein G, Winberg G. Parallel existence of Epstein-Barr virus (EBV) positive and negative cells in a sporadic case of Burkitt lymphoma. *Oncogene*. 1995 Aug 3;11(3):505-10. (I.F. 6.634 J Citation Reports, Cit: 11 Scopus)
- 11: **Trivedi P**, Winberg G, Klein G. Differential immunogenicity of Epstein-Barr virus (EBV) encoded growth transformation-associated antigens in a murine model system. *Eur J Cancer*. 1997 May;33(6):912-7. doi: 10.1016/s0959-8049(96)00514-x. PubMed PMID: 9291815. (I. F. 6.680, J Citation Report, Cit: 12 Scopus)
- 12: Pokrovskaja K, **Trivedi P**, Klein G, Szekely L. Epstein-Barr virus-encoded LMP-1 protein upregulates the pNDCF group of nucleoskeleton-cytoskeleton-associated proteins. *J Gen Virol*. 1997 Aug;78 ( Pt 8):2031-40. doi: 10.1099/0022-1317-78-8-2031. (I. F. 2.809, J Citation Report, Cit: 3 Scopus)
- 13: Mukherjee S, **Trivedi P**, Dorfman DM, Klein G, Townsend A. Murine cytotoxic T lymphocytes recognize an epitope in an EBNA-1 fragment, but fail to lyse EBNA-1-expressing mouse cells. *J Exp Med*. 1998 Feb 2;187(3):445-50. doi: 10.1084/jem.187.3.445. (I.F. 10.892, J Citation Report, Cit: 29 Scopus)
- 14: Cuomo L, Trivedi P, de Grazia U, Calogero A, D'Onofrio M, Yang W, Frati L, Faggioni A, Rymo L, Ragona G. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells. *J Med Virol*. 1998 Jul;55(3):219-26. (I.F. 2.049, J Citation Report, Cit: 17)
- 15: Charo J, Ciupitu AM, Le Chevalier De Préville A, Trivedi P, Klein G, Hinkula J, Kiessling R. A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene. *J Immunol*. 1999 Dec 1;163(11):5913-9. PubMed PMID: 10570277. (I.F. 4.718, J Citation report, Cit: 21 Scopus)
- 16: **Trivedi P**, Cuomo L, Christensson B, Hu LF, Morrone S, Frati L, Faggioni A, Winberg G, Klein G. Augmentation of leukocyte infiltration in murine tumors expressing B-cell derived but not nasopharyngeal carcinoma derived EBV membrane protein LMP1. *J Med Virol*. 2000 Apr;60(4):417-24. (I. F. 2.049, J Citation Report, Cit: 5 Scopus)
- 17: Hu L, Troyanovsky B, Zhang X, **Trivedi P**, Ernberg I, Klein G. Differences in the immunogenicity of latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus genomes



- derived from LMP1-positive and -negative nasopharyngeal carcinoma. *Cancer Res.* 2000 Oct 1;60(19):5589-93. (I. F. 8.378, J Citation Report, Cit: 32 Scopus)
- 18: Cuomo L\*, **Trivedi P\***, Cardillo MR, Gagliardi FM, Vecchione A, Caruso R, Calogero A, Frati L, Faggioni A, Ragona G. Human herpesvirus 6 infection in neoplastic and normal brain tissue. *J Med Virol.* 2001 Jan;63(1):45-51. (I.F. 2.049, J Citation Report, Cit: 97 Scopus), \*equal contribution
- 19: **Trivedi P**, Spinsanti P, Cuomo L, Volpe M, Takada K, Frati L, Faggioni A. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain. *J Virol.* 2001 May;75(10):4929-35. doi: 10.1128/JVI.75.10.4929-4935.2001. (I.F. 4.324, J Citation Report, Cit: 18 Scopus)
- 20: Nagy N, Maeda A, Bandobashi K, Kis LL, Nishikawa J, **Trivedi P**, Faggioni A, Klein G, Klein E. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation. *Int J Cancer.* 2002 Aug 1;100(4):433-40. doi: 10.1002/ijc.10498. (I.F. 4.982, J Citation Report, Cit: 30 Scopus)
- 21: Barile G, Di Certo MG, **Trivedi P**, Faggioni A. Possible steps required in the internalization of nude Epstein-Barr virus. *Cell Biol Int.* 2003;27(1):61-5. Review. (I.F. 1.092, J Citation Report, Cit: 0)
- 22: Kiss C, Nishikawa J, Takada K, **Trivedi P**, Klein G, Szekely L. T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines. *Proc Natl Acad Sci U S A.* 2003 Apr 15;100(8):4813-8. doi: 10.1073/pnas.0730710100. Epub 2003 Apr 2. (I.F. 9.580, J Citation Report, Cit: 29 Scopus)
- 23: **Trivedi P**, Takazawa K, Zompetta C, Cuomo L, Anastasiadou E, Carbone A, Uccini S, Belardelli F, Takada K, Frati L, Faggioni A. Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. *Blood.* 2004 Jan 1;103(1):313-6. doi: 10.1182/blood-2003-05-1710. (I.F. 16.681, J Citation Report, Cit: 40 Scopus)
- 24: Colangelo V, Gordon WC, Mukherjee PK, **Trivedi P**, Ottino P. Downregulation of COX-2 and JNK expression after induction of ischemic tolerance in the gerbil brain. *Brain Res.* 2004 Aug 6;1016(2):195-200. doi: 10.1016/j.brainres.2004.05.017. (I. F. 2.929, J Citation Report, Cit: 16 Scopus)
- 25: Anastasiadou E, Boccellato F, Cirone M, Kis LL, Klein E, Frati L, Faggioni A, **Trivedi P**. Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein-Barr virus. *Leukemia.* 2005 Oct;19(10):1854-6. doi: 10.1038/sj.leu.2403895. (I. F. 9.944, J Citation Report, Cit: 6 Scopus)
- 26: Boccellato F, Anastasiadou E, Rosato P, Kempkes B, Frati L, Faggioni A, **Trivedi P**. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells. *J Virol.* 2007 Mar;81(5):2274-82. doi: 10.1128/JVI.01822-06. (I.F. 4.324, J Citation Report, Cit: 25 Scopus)
- 27: Xu D, Coleman T, Zhang J, Fagot A, Kotalik C, Zhao L, **Trivedi P**, Jones C, Zhang L. Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. *J Virol.* 2007 Jun;81(11):6068-78. doi: 10.1128/JVI.02743-06. (I.F. 4.324 J Citation Report, Cit: 37 Scopus)



- 28: Cirone M, Lucania G, Bergamo P, **Trivedi P**, Frati L, Faggioni A. [Human herpesvirus 8 \(HHV-8\) inhibits monocyte differentiation into dendritic cells and impairs their immunostimulatory activity](#). *Immunol Lett.* 2007 Oct 31;113(1):40-6. doi: 10.1016/j.imlet.2007.07.013. **(I. F. 2.552 J Citation Report, Cit: 28 Scopus)**
- 29: Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, **Trivedi P**, Salvetti M, Faggioni A, Aloisi F. [Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain](#). *J Exp Med.* 2007 Nov 26;204(12):2899-912. doi: 10.1084/jem.20071030. **(I. F. 10.892 J Citation Report, Cit: 489 Scopus)**
- 30: Cirone M, Lucania G, Aleandri S, Borgia G, **Trivedi P**, Cuomo L, Frati L, Faggioni A. [Suppression of dendritic cell differentiation through cytokines released by Primary Effusion Lymphoma cells](#). *Immunol Lett.* 2008 Oct 30;120(1-2):37-41. doi: 10.1016/j.imlet.2008.06.011. **(I.F. 2.552, J Citation Reports, Cit: 33 Scopus)**
- 31: Anastasiadou E, Vaeth S, Cuomo L, Boccellato F, Vincenti S, Cirone M, Presutti C, Junker S, Winberg G, Frati L, Wade PA, Faggioni A, **Trivedi P**. [Epstein-Barr virus infection leads to partial phenotypic reversion of terminally differentiated malignant B cells](#). *Cancer Lett.* 2009 Nov 1;284(2):165-74. doi: 10.1016/j.canlet.2009.04.025. **(I.F. 6.508, J Citation Reports, Cit: 21 Scopus)**
- 32: Anastasiadou E, Boccellato F, Vincenti S, Rosato P, Bozzoni I, Frati L, Faggioni A, Presutti C, **Trivedi P**. [Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b](#). *Oncogene.* 2010 Mar 4;29(9):1316-28. doi: 10.1038/onc.2009.439 . **(I.F. 6.634, J Citation Reports, Cit: 44 Scopus)**
- 33: Cirone M, Di Renzo L, **Trivedi P**, Lucania G, Borgia G, Frati L, Faggioni A. [Dendritic cell differentiation blocked by primary effusion lymphoma-released factors is partially restored by inhibition of P38 MAPK](#). *Int J Immunopathol Pharmacol.* 2010 Oct-Dec;23(4):1079-86. doi: 10.1177/039463201002300412. **(I.F. 2.117 J Citation Report, Cit: 12 Scopus)**
- 34: Imig J, Motsch N, Zhu JY, Barth S, Okoniewski M, Reineke T, Tinguely M, Faggioni A, **Trivedi P**, Meister G, Renner C, Grässer FA. [microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma](#). *Nucleic Acids Res.* 2011 Mar;39(5):1880-93. doi: 10.1093/nar/gkq1043. **(I.F. 11.147, J Citation Reports, Cit: 118 Scopus)**
- 35: Cirone M, Di Renzo L, Lotti LV, Conte V, **Trivedi P**, Santarelli R, Gonnella R, Frati L, Faggioni A. [Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91](#). *PLoS One.* 2012;7(3):e31732. doi: 10.1371/journal.pone.0031732. **(I.F. 2.776 J Citation Reports, Cit: 64 Scopus)**
- 36: Cirone M, Conte V, Farina A, Valia S, **Trivedi P**, Granato M, Santarelli R, Frati L, Faggioni A. [HHV-8 reduces dendritic cell migration through down-regulation of cell-surface CCR6 and CCR7 and cytoskeleton reorganization](#). *Viol J.* 2012 May 14;9:92. doi: 10.1186/1743-422X-9-92. **(I.F. 2.464 J Citation Report, Cit: 17 Scopus)**
- 37: Kwanhian W, Lenze D, Alles J, Motsch N, Barth S, Döll C, Imig J, Hummel M, Tinguely M, **Trivedi P**, Lulitanond V, Meister G, Renner C, Grässer FA. [MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma](#). *Cancer Med.* 2012 Oct;1(2):141-55. doi: 10.1002/cam4.29. **(I.F. 3.357 J Citation Reports 2014, Cit: 46 Scopus)**

- 38: Cirone M, Di Renzo L, Lotti LV, Conte V, **Trivedi P**, Santarelli R, Gonnella R, Frati L, Faggioni A. [Activation of dendritic cells by tumor cell death](#). *Oncoimmunology*. 2012 Oct 1;1(7):1218-1219. doi: 10.4161/onci.20428. **(I.F. 5.333 J Citation Reports, Cit: 28 Scopus)**
- 39: Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S, Severa M, Coccia EM, Bigi R, Cirone M, Ferretti E, Campese AF, Hummel M, Frati L, Presutti C, Faggioni A, **Trivedi P**. [Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2](#). *Leukemia*. 2012 Nov;26(11):2343-52. doi: 10.1038/leu.2012.108. **(I.F. 9.944 J Citation Reports, Cit: 61 Scopus)**
- 40: Severa M, Giacomini E, Gafa V, Anastasiadou E, Rizzo F, Corazzari M, Romagnoli A, **Trivedi P**, Fimia GM, Coccia EM. [EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape](#). *Eur J Immunol*. 2013 Jan;43(1):147-58. doi: 10.1002/eji.201242552. **(I.F. 4.518, J Citation Reports, Cit: 59 Scopus)**
- 41: Granato M, Lacconi V, Peddis M, Lotti LV, Di Renzo L, Gonnella R, Santarelli R, Trivedi P, Frati L, D'Orazi G, Faggioni A, Cirone M. [HSP70 inhibition by 2-phenylethanesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma](#). *Cell Death Dis*. 2013 Jul 18;4:e730. doi: 10.1038/cddis.2013.263. **(I.F. 5.959 J Citation Reports, Cit: 54 Scopus)**
- 42: Granato M, Santarelli R, Lotti LV, Di Renzo L, Gonnella R, Garufi A, **Trivedi P**, Frati L, D'Orazi G, Faggioni A, Cirone M. [JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells](#). *PLoS One*. 2013;8(9):e75965. doi: 10.1371/journal.pone.0075965. eCollection 2013. **(I.F. 2.776 J Citation Reports, Cit: 33 Scopus)**
- 43: Di Napoli A, Al-Jadiri MF, Talerico C, Duranti E, Pillozzi E, **Trivedi P**, Anastasiadou E, Alsaadawi AR, Al-Darraj AF, Al-Hadad SA, Testi AM, Uccini S, Ruco L. [Epstein-Barr virus \(EBV\) positive classical Hodgkin lymphoma of Iraqi children: an immunophenotypic and molecular characterization of Hodgkin/Reed-Sternberg cells](#). *Pediatr Blood Cancer*. 2013 Dec;60(12):2068-72. doi: 10.1002/pbc.24654. **(I.F. 2.486 J Citation Reports, Cit: 20 Scopus)**
- 44: Cuomo L, Cirone M, Di Gregorio AO, Vitillo M, Cattivelli M, Magliocca V, Maiorano S, Meledandri M, Scagnolari C, La Rocca S, **Trivedi P**. [Elevated antinuclear antibodies and altered anti-Epstein-Barr virus immune responses](#). *Virus Res*. 2015 Jan 2;195:95-9. doi: 10.1016/j.virusres.2014.09.014. **(I.F. 2.736 J Citation Reports, Cit: 8 Scopus)**
- 45: Granato M, Santarelli R, Gonnella R, Farina A, **Trivedi P**, Faggioni A, Cirone M. [Targeting of prosurvival pathways as therapeutic approaches against primary effusion lymphomas: past, present, and future](#). *Biomed Res Int*. 2015;2015:104912. doi: 10.1155/2015/104912. Epub 2015 Jan 28. Review. **(I.F. 2.197 J Citation Reports, Cit: 8 Scopus)**
- 46: Anastasiadou E, Garg N, Bigi R, Yadav S, Campese AF, Lapenta C, Spada M, Cuomo L, Botta A, Belardelli F, Frati L, Ferretti E, Faggioni A, **Trivedi P**. [Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells](#). *Int J Cancer*. 2015 Sep 15;137(6):1491-7. doi: 10.1002/ijc.29489. **(I.F. 4.982 J Citation Reports, Cit: 23 Scopus)**
- 47: Anastasiadou E, Faggioni A, **Trivedi P**, Slack FJ. [The Nefarious Nexus of Noncoding RNAs in Cancer](#). *Int J Mol Sci*. 2018 Jul 17;19(7). doi: 10.3390/ijms19072072. Review. **(I.F: 4.183 J Citation Reports, Cit: 22 Scopus)**

48: **Trivedi P**, Slack FJ, Anastasiadou E. [Epstein-Barr virus: From kisses to cancer, an ingenious immune evader](#). *Oncotarget*. 2018 Nov 23;9(92):36411-36412. doi: 10.18632/oncotarget.26381. eCollection 2018 Nov 23. **(I.F. 5.168 J Citation Reports 2016, Cit: 1, Scopus)**

49: Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia EM, Sui SJH, Chen CS, Uccini S, Avigan D, Faggioni A, **Trivedi P\***, Slack FJ\*. [Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas](#). *Leukemia*. 2019 Jan;33(1):132-147. doi: 10.1038/s41375-018-0178-x. Epub 2018 Jun 26. **(I.F. 9.944, J Citation Reports, Cit: 40 Scopus)**, \*co-senior author and co-corresponding author.

50: Ayoubian H, Ludwig N, Fehlmann T, Menegatti J, Gröger L, Anastasiadou E, **Trivedi P**, Keller A, Meese E, Grässer FA. [Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex](#). *J Virol*. 2019 Feb 1;93(3). doi: 10.1128/JVI.01297-18. Print 2019 Feb 1. **(I.F. 4.324, J Citation Report, Cit: 3 Scopus)**

51: Severa M, Rizzo F, Srinivasan S, Di Dario M, Giacomini E, Buscarinu MC, Cruciani M, Etna MP, Sandini S, Mechelli R, Farina A, **Trivedi P**, Hertzog PJ, Salvetti M, Farina C, Coccia EM. [A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis](#). *J Autoimmun*. 2019 Jul;101:1-16. doi: 10.1016/j.jaut.2019.04.006. Epub 2019 Apr 30. **(I.F. 7.543, J Citation Report, Cit: 6 Scopus)**

52: Manchala NR, Dungdung R, **Trivedi P**, Unniyampurath U, Pilankatta R. [Mycophenolic acid \(MPA\) modulates host cellular autophagy progression in sub genomic dengue virus-2 replicon cells](#). *Microb Pathog*. 2019 Sep 24;137:103762. doi: 10.1016/j.micpath.2019.103762. [Epub ahead of print] PubMed PMID: 31560972. **(I.F. 2.581, J Citation Report, Cit: 1 Scopus)**

53: Anastasiadou E, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC, Pestano L, Marchese C, Avigan D, **Trivedi P**, Escolar DM, Jackson AL, Slack FJ. [Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo](#). *Clin Cancer Res*. 2020 Nov 18. doi: 10.1158/1078-0432.CCR-20-3139. Online ahead of print. (IF 10.107, Cit:0)

54: De Luca R, Davis PJ, Lin HY, Gionfra F, Percario ZA, Affabris E, Pedersen JZ, Marchese C, **Trivedi P**, Anastasiadou E, Negro R, Incerpi S. [Thyroid Hormones Interaction With Immune Response, Inflammation and Non-thyroidal Illness Syndrome](#). *Front Cell Dev Biol*. 2021 Jan 21;8:614030. doi: 10.3389/fcell.2020.614030. eCollection 2020 (IF 5.201, Cit:0)

55: Anastasiadou E, Messina E, Sanavia T, Mundo L, Farinella F, Lazzi S, Megiorni F, Ceccarelli S, Pontecorvi P, Marampon F, Di Gioia CRT, Perniola G, Panici PB, Leoncini L, Trivedi P, Lenzi A, Marchese C. [MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of  \$\beta\$ -Catenin and c-Myc](#). *Cells*. 2021 Mar 1;10(3). doi: 10.3390/cells10030519. PubMed PMID: 33804458; PubMed Central PMCID: PMC7998372.

56: Trivedi P, Patel SK, Bellavia D, Messina E, Palermo R, Ceccarelli S, Marchese C, Anastasiadou E, Minter LM, Felli MP. [When Viruses Cross Developmental Pathways](#). *Front Cell Dev Biol*. 2021;9:691644. doi: 10.3389/fcell.2021.691644. eCollection 2021. Review. PubMed PMID: 34422814; PubMed Central PMCID: PMC8375270.

- 57: Anastasiadou E, Messina E, Sanavia T, Labruna V, Ceccarelli S, Megiorni F, Gerini G, Pontecorvi P, Camero S, Perniola G, Venneri MA, Trivedi P, Lenzi A, Marchese C. [Calcineurin Gamma Catalytic Subunit PPP3CC Inhibition by miR-200c-3p Affects Apoptosis in Epithelial Ovarian Cancer](#). *Genes (Basel)*. 2021 Sep 10;12(9). doi: 10.3390/genes12091400. PubMed PMID: 34573382; PubMed Central PMCID: PMC8470066.
- 58: Anastasiadou E, Ceccarelli S, Messina E, Gerini G, Megiorni F, Pontecorvi P, Camero S, Onesti MG, Trivedi P, Faenza M, Coscioni E, Nicoletti GF, Napoli C, Marchese C. [MiR-200c-3p maintains stemness and proliferative potential in adipose-derived stem cells by counteracting senescence mechanisms](#). *PLoS One*. 2021;16(9):e0257070. doi: 10.1371/journal.pone.0257070. eCollection 2021. PubMed PMID: 34534238; PubMed Central PMCID: PMC8448302.
- 59: Cuomo L, Vitillo M, Della Rocca M, Trivedi P. [Comparative analysis of three methods in anti-dsDNA antibodies detection: implications for Systemic Lupus Erythematosus diagnosis](#). *Scand J Immunol*. 2022 Feb;95(2):e13123. doi: 10.1111/sji.13123. Epub 2021 Dec 12. PubMed PMID: 34865261.
- 60: Benedetti R, Arena A, Romeo MA, Gilardini Montani MS, Gonnella R, Santarelli R, Trivedi P, Cirone M. [Concomitant Inhibition of IRE1 \$\alpha\$ /XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas](#). *Int J Mol Sci*. 2022 Aug 14;23(16). doi: 10.3390/ijms23169113. PubMed PMID: 36012375; PubMed Central PMCID: PMC9409055.